NCI Drug Dictionary
The NCI Drug Dictionary contains technical definitions and synonyms for drugs/agents used to treat patients with cancer or conditions related to cancer. Each drug entry includes links to check for clinical trials listed in NCI's List of Cancer Clinical Trials.
- BCMA x CD3 T-cell-engaging antibody CC-93269
A bispecific T-cell engager (BiTE) antibody composed of two single-chain variable fragments (scFv), one directed against the tumor-associated antigen (TAA) human B-cell maturation antigen (BCMA; TNFRSF17), and one that is directed against the CD3 antigen found on T lymphocytes, with potential immunostimulating and antineoplastic activities. Upon administration of anti-BCMA/CD3 T-cell engaging antibody CC-93269, this bispecific antibody binds to both CD3 on cytotoxic T lymphocytes (CTLs) and BCMA found on BCMA-expressing tumor cells. This activates and redirects CTLs to BCMA-expressing tumor cells, which results in the CTL-mediated death of BCMA-expressing tumor cells. BCMA, a member of the tumor necrosis factor receptor superfamily that is specifically overexpressed on malignant plasma cells, plays a key role in promoting plasma cell survival.
Check for active clinical trials using this agent. (NCI Thesaurus)
Synonym: anti-BCMA/CD3 bispecific antibody CC-93269
BCMA x CD3 T Cell-engaging antibody CC-93269
BCMA/CD3 T-cell bi-specific antibody CC-93269
BCMA/CD3-directed bispecific T-cell engager antibody CC-93269
BCMAxCD3 BiTE antibody CC-93269
BCMAxCD3 TCB CC-93269
bi-specific antibody CC-93269
Code name: CC 93269